ArticleBritish journal of cancer2020
Patient-derived xenograft models-the future of personalised cancer treatment.
Article in British journal of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Beyond the mouse: 3R-guided alternative animal models transforming cancer research.Molecular cancer · 2026Review
- From 2D cultures to 3D systems: evolving cancer models at the interface of functional precision medicine and theranostics.Theranostics · 2026Review
- Establishing a pediatric solid tumor PDX biobank for precision oncology research.Cancer biology & therapy · 2025Article
- Unveiling Another Dimension: Advanced Visualization of Cancer Invasion and Metastasis via Micro-CT Imaging.Cancers · 2025Article
- Baicalin reduces sunitinib-induced cardiotoxicity in renal carcinoma PDX model by inhibiting myocardial injury, apoptosis and fibrosis.Frontiers in pharmacology · 2025Article
- Pharmacoproteogenomic approach identifies on-target kinase inhibitors for cancer drug repositioning.In vitro cellular & developmental biology. Animal · 2024Article
- ALK inhibitors suppress HCC and synergize with anti-PD-1 therapy and ABT-263 in preclinical models.iScience · 2024Article
- Assessing Protein Expression in Patient-Derived Xenografts Using Western Blotting.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Rhabdomyosarcoma: Current Therapy, Challenges, and Future Approaches to Treatment Strategies.Cancers · 2023Review
- Cancer treatment therapies: traditional to modern approaches to combat cancers.Molecular biology reports · 2023Review
- PROBABILISTIC LEARNING OF TREATMENT TREES IN CANCER.The annals of applied statistics · 2023Article
- Patient-derived intrafemoral orthotopic xenografts of peripheral blood or bone marrow from acute myeloid and acute lymphoblastic leukemia patients: clinical characterization, methodology, and validation.Clinical and experimental medicine · 2023Article
- Article
- Development and characterization of a patient‑derived orthotopic xenograft of therapy‑resistant breast cancer.Oncology reports · 2023Article
- A new tumorgraft panel to accelerate precision medicine in prostate cancer.Frontiers in oncology · 2023Article
- 3D cancer models: One step closer toFrontiers in immunology · 2023Review
- Patient-derived organoids (PDOs) and PDO-derived xenografts (PDOXs): New opportunities in establishing faithful pre-clinical cancer models.Journal of the National Cancer Center · 2022Review
- Predictive validity in drug discovery: what it is, why it matters and how to improve it.Nature reviews. Drug discovery · 2022Review
- Assessing the performance of different outcomes for tumor growth studies with animal models.Animal models and experimental medicine · 2022Article
- Evaluating Translational Methods for Personalized Medicine-A Scoping Review.Journal of personalized medicine · 2022Article
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
Abstract
For many tumours there is a lack of randomised data from which we can guide systemic treatments. Although gene expression profiling along with proteomics has led to advances in diagnosis, classification and prognosis, our ability to target many cancers has been further limited due to a lack of therapeutic options. The use of patient-derived xenograft (PDX) models in the setting of a rare malignancy is discussed here by Kamili et al, with the successful establishment of new model systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.